TRV-120027
Also known as: TRV-027, TRV‑120027, TRV027, TRV120027
Source TRV-120027 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
TRV‑120027 (also known as TRV027) is a synthetic, modified angiotensin II peptide designed as a β‑arrestin‑biased agonist of the AT1 receptor. It was evaluated in Phase 2 trials for acute decompensated heart failure but has not received regulatory approval.
Mechanism of Action
Selective activation of β‑arrestin signaling at the angiotensin II type 1 receptor (AT1R) while antagonizing G‑protein pathways, leading to vasodilation and enhanced cardiac output
Routes of Administration
Goals & Uses
- Cardiomyocyte cytoprotectionCardioprotectionLow
- Acute decompensated heart failureCardiovascularModerate
- Reduction of dyspnea in acute heart failureCardiovascular / HemodynamicModerate
- Reduction of preload/afterloadHemodynamicModerate
- Reduction of cardiac preload and afterloadCardiovascular / HemodynamicModerate
- Renal protection during AHF treatmentRenal / Organ ProtectionLow
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Concurrent use of potent vasodilatorsPharmacologicModerate
- Hypotension (severe)HemodynamicHigh
- Severe bilateral renal artery stenosisRenalHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypotensionCardiovascularCommonLow blood pressure
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
- Worsening renal functionRenalUncommon
Drug Interactions
- Antihypertensive agentsModerate
- Angiotensin Receptor Blockers (ARBs)Low
- ACE inhibitorsModerate
- Potassium-sparing diureticsModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric populationAgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization granted
- United StatesInvestigationalPhase 2 completed; not submitted for FDA approval
- United KingdomUnapprovedNo regulatory submission or approval in the United Kingdom.
Completed Phase 2 studies; not submitted for marketing authorization in major jurisdictions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is TRV-120027?
TRV‑120027 (also known as TRV027) is a synthetic, modified angiotensin II peptide designed as a β‑arrestin‑biased agonist of the AT1 receptor. It was evaluated in Phase 2 trials for acute decompensated heart failure but has not received regulatory approval.
What is TRV-120027 used for?
TRV-120027 is educationally associated with: Cardiomyocyte cytoprotection, Acute decompensated heart failure, Reduction of dyspnea in acute heart failure, Reduction of preload/afterload, Reduction of cardiac preload and afterload, Renal protection during AHF treatment. Educational only — not medical advice.
How is TRV-120027 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of TRV-120027?
Reported adverse effects include: Headache, Hypotension, Nausea, Dizziness, Worsening renal function. This list is not exhaustive — consult a qualified clinician.
Who should avoid TRV-120027?
Recorded contraindications: Pregnancy, Concurrent use of potent vasodilators, Hypotension (severe), Severe bilateral renal artery stenosis, Severe hypotension. Consult a qualified clinician before use.